PT - JOURNAL ARTICLE AU - , AU - Parker, Edward PK AU - Tazare, John AU - Hulme, William J AU - Bates, Christopher AU - Beale, Rupert AU - Carr, Edward J AU - Cockburn, Jonathan AU - Curtis, Helen J AU - Fisher, Louis AU - Green, Amelia CA AU - Harper, Sam AU - Hester, Frank AU - Horne, Elsie MF AU - Loud, Fiona AU - Lyon, Susan AU - Mahalingasivam, Viyaasan AU - Mehrkar, Amir AU - Nab, Linda AU - Parry, John AU - Santhakumaran, Shalini AU - Steenkamp, Retha AU - Sterne, Jonathan AC AU - Walker, Alex J AU - Williamson, Elizabeth J AU - Willicombe, Michelle AU - Zheng, Bang AU - Goldacre, Ben AU - Nitsch, Dorothea AU - Tomlinson, Laurie A TI - Factors associated with COVID-19 vaccine uptake in people with kidney disease: an OpenSAFELY cohort study AID - 10.1101/2022.06.14.22276391 DP - 2022 Jan 01 TA - medRxiv PG - 2022.06.14.22276391 4099 - http://medrxiv.org/content/early/2022/06/16/2022.06.14.22276391.short 4100 - http://medrxiv.org/content/early/2022/06/16/2022.06.14.22276391.full AB - Background Kidney disease is a significant risk factor for COVID-19-related mortality. Achieving high COVID-19 vaccine coverage among people with kidney disease is therefore a public health priority.Methods With the approval of NHS England, we performed a retrospective cohort study using the OpenSAFELY-TPP platform. Individual-level routine clinical data from 24 million people in England were included. A cohort of individuals with stage 3–5 chronic kidney disease (CKD) or receiving renal replacement therapy (RRT) at the start of the COVID-19 vaccine roll-out was identified based on evidence of reduced estimated glomerular filtration rate or inclusion in the UK Renal Registry. Individual-level factors associated with vaccine uptake were explored via Cox proportional hazards models.Results 948,845 people with stage 3–5 CKD or receiving RRT were included. Cumulative vaccine coverage as of 11th May 2022 was 97.5%, 97.0%, and 93.5% for doses 1, 2, and 3, respectively, and 61.1% among individuals with one or more indications for receipt of a fourth dose. Delayed 3-dose vaccine uptake was associated with non-White ethnicity, social deprivation, and severe mental illness – associations that were consistent across CKD stages and in RRT recipients. Similar associations were observed for 4-dose uptake, which was also delayed among care home residents.Conclusion Although high primary and booster dose coverage has been achieved among people with kidney disease in England, key disparities in vaccine uptake remain across demographic groups. Identifying how to address these disparities remains a priority to reduce the risk of severe disease in this vulnerable patient group.Competing Interest StatementBG's work on better use of data in healthcare more broadly is currently funded in part by: the Bennett Foundation, the Wellcome Trust, NIHR Oxford Biomedical Research Centre, NIHR Applied Research Collaboration Oxford and Thames Valley, the Mohn-Westlake Foundation; all Bennett Institute staff are supported by BG's grants on this work. BG is a Non-Executive Director at NHS Digital. EJW holds grants from MRC.Funding StatementThis work was jointly funded by the Wellcome Trust (222097/Z/20/Z); MRC (MR/V015757/1, MC_PC-20059, MR/W016729/1); NIHR (NIHR135559, COV-LT2-0073), and Health Data Research UK (HDRUK2021.000, 2021.0157).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Health Research Authority (REC reference 20/LO/0651) and by the London School of Hygiene & Tropical Medicine's Ethics Board (reference 21863).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDetailed pseudonymised patient data is potentially re-identifiable and therefore not shared. https://github.com/opensafely/ckd-coverage-ve